SUMO-1 [6His-tagged]

Modifying Protein

Alternate Names: SMT3C, SMT3H3, UBL1, PIC1, GMP1, OFC10 and sentrin

Cat. No.	60-0002-500
Lot. No.	1364

Quantity: 500 µg Storage: -70°C

NOT FOR USE IN HUMANS

FOR RESEARCH USE ONLY

Small Ubiquitin-like Modifiers (SUMOs)

are a family of small, related proteins

that can be enzymatically conjugated to

a target protein by a post-translational

modification process termed SUMOylation. SUMO-1 is a highly conserved,

small ubiquitin-related modifier that has

been shown to be covalently conjugat-

ed to a large variety of cellular proteins

(Kamitani et al., 1997; Mahajan et al.,

1997; Matunis et al., 1996). Cloning of

SUMO-1 was first described by Boddy et al. (1996). SUMO-2 and SUMO-3

share 95% sequence identity, but only 50% sequence identity to SUMO-1.

SUMO-1 is conjugated to a target pro-

tein in a similar way to ubiquitin and has been implicated in multiple cellular processes, including nuclear transport,

cell cycle control, oncogenesis, inflam-

mation and response to viral infection.

SUMO-1 conjugation forms an isopep-

tide bond between Gly97 at the C-termi-

nus of SUMO-1 and the ε -amino group

on the Lysine side chain of the target

protein; however it is unable to form

multi-chain species (Bayer et al., 1998;

Mahajan et al., 1997; Mahajan et al.,

1998). SUMO-1 targets substrates in-

cluding RanGAP1, PML, Sp100, HSF1,

Smad4, IkBa, c-Jun, p53 and Mdm2

(Melchior. 2000). RanGAP1, a Ran

GTPase-activating is a major SUMO-1 substrate protein involved in nucleocy-

toplasmic trafficking (Swaminathan et

al., 2004). SUMO-1 covalently modifies a single lysine residue at position 526

in the C-terminus of RanGAP1 (Ma-

hajan et al., 1997; Matunis et al., 1996;

Background

Physical Characteristics

Species: human

Source: E. coli expression

Quantity: 500 µg

Concentration: 1 mg/ml

Formulation: 50 mM HEPES pH 7.5, 150 mM sodium chloride, 2 mM dithiothreitol, 10% glycerol

Molecular Weight: ~13.5 kDa


Purity: >98% by InstantBlue™ SDS-PAGE

Stability/Storage: 12 months at -70°C; aliquot as required

Quality Assurance

Purity:

4-12% gradient SDS-PAGE InstantBlue™ staining Lane 1: MW markers Lane 2: 1 μg His-SUMO-1



Protein Sequence:

UBIQUIGENT

CERTIFICATE OF ANALYSIS Page 1 of 2

MGSSHHHHHHSSGLEVLFQGPGSMSDQEAKPST EDLGDKKEGEYIKLKVIGQDSSEIHFKVKMTTH LKKLKESYCQRQGVPMNSLRFLFEGQRIADNHTP KELGMEEEDVIEVYQEQTGG

Tag (**bold text**): N-terminal His Protease cleavage site: PreScission™ (<u>LEVLFQ▼GP</u>) SUMO-1 (regular text): Start **bold italics** (amino acid residues 1-97) Accession number: NP_003343

Protein Identification:

Confirmed by mass spectrometry.

E2 Thioester SUMO-1 Loading Assay:

The activity of His-SUMO-1 was validated by loading His-SUMO-1 onto the active cysteine of the UBE2I E2 enzyme via a transthiolation reaction. Incubation of His-SUMO-1, SAE1/SAE2 and UBE2I enzymes in the presence of ATP at 30°C was compared at two time points, T_0 and T_{10} minutes. Sensitivity of the His-SUMO-1/UBE2I thioester bond to the reducing agent DTT was confirmed.



Continued on page 2

ORDERS / SALES SUPPORT International: +1-617-245-0003 US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233) Email: sales.support@ubiquigent.com UK HQ and TECHNICAL SUPPORT

 International:
 +44 (0) 1382 381147
 (9AM-5PM UTC)

 US/Canada:
 +1-617-245-0020
 (9AM-5PM UTC)

 Email:
 tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services. © Ubiquigent 2011. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

SUMO-1 [6His-tagged]

60-0002-500

Modifying Protein

Alternate Names: SMT3C, SMT3H3, UBL1, PIC1, GMP1, OFC10 and sentrin



FOR RESEARCH USE ONLY

1364

NOT FOR USE IN HUMANS

500 μg -70°C

Quantity:

Storage:

CERTIFICATE OF ANALYSIS Page 2 of 2

Background

Cat. No.

Lot. No.

Continued from page 1

Muller *et al.*, 1998). SUMO-1 modified RanGAP1 has been found tightly associated with the nuclear envelope (Mahajan *et al.*, 1997; Matunis *et al.*, 1996) an observation which supports its role in nucleocytoplasmic trafficking.

References:

Bayer P, Arndt A, Metzger S, Mahajan R, Melchior F, Jaenicke R, Becker J (1998) Structure determination of the small ubiquitin-related modifier SUMO-1. *J Mol Biol* **280**, 275-86.

Boddy MN, Howe K, Etkin LD, Solomon E, Freemont PS (1996) PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. *Oncogene* **13**, 971-82.

Kamitani T, Nguyen HP, Yeh ET (1997) Preferential modification of nuclear proteins by a novel ubiquitin-like molecule. *J Biol Chem* 272, 14001-4.

Mahajan R, Delphin C, Guan T, Gerace L, Melchior F (1997) A small ubiquitin-related polypeptide involved in targeting Ran-GAP1 to nuclear pore complex protein RanBP2. *Cell* **88**, 97-107.

Mahajan R, Gerace L, Melchior F (1998) Molecular characterization of the SUMO-1 modification of RanGAP1 and its role in nuclear envelope association. *J Cell Biol* **140**, 259-70.

Matunis MJ, Coutavas E, Blobel G (1996) A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J Cell Biol **135**, 1457-70.

Melchior F (2000) SUMO--nonclassical ubiquitin. Annu Rev Cell Dev Biol 16, 591-626.



ORDERS / SALES SUPPORT

 International:
 +1-617-245-0003

 US Toll-Free:
 1-888-4E1E2E3 (1-888-431-3233)

 Email:
 sales.support@ubiquigent.com

UK HQ and TECHNICAL SUPPORT

 International:
 +44 (0) 1382 381147
 (9AM-5PM UTC)

 US/Canada:
 +1-617-245-0020
 (9AM-5PM UTC)

 Email:
 tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2011. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative QR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0